Osteoimmunology: The RANKL-OPG Axis & Bone Erosion

The immune system never talks to bone directly. This is the organising fact of the field and the reason it needed a name of its own. IL-17A has no receptor on the osteoclast; it induces RANKL on osteoblasts and synoviocytes. IL-6 does the same, which is why tocilizumab slows radiographic progression rather than only relieving symptoms. TNF is the partial exception \u2014 it also lowers the threshold at which a precursor responds to RANKL \u2014 and that direct contribution is the most plausible explanation for why anti-TNF treatment halts erosion faster than it resolves synovitis. The practical consequence is that blocking an upstream cytokine only partly works: RANKL is produced by osteoblasts, osteocytes, activated T cells and synovial fibroblasts, four sources with different regulation, and removing one leaves the others.

Only the ratio means anything. Osteoprotegerin is a soluble decoy receptor for RANKL made by the same osteoblast lineage that makes RANKL itself, so neither concentration predicts turnover on its own. Reporting one without the other is the most common error in this literature. A second frequently omitted requirement is M-CSF: RANKL cannot make an osteoclast unaided, because M-CSF must first keep the precursor alive and induce RANK on it. Two signals in a required order, which is why blocking CD115/CSF1R and blocking RANKL are different experiments with different meanings \u2014 one removes the precursor pool, the other removes the instruction. And the T cell is not uniformly pro-erosive: Th17 cells drive the axis through IL-17A, while IFN-\u03b3 from Th1 cells degrades TRAF6 and opposes it, so depleting T cells wholesale can go either way.

Commitment is a switch, not a dial. c-Fos decides between the osteoclast and the macrophage fate from the same precursor under the same signals, and NFATc1 then autoamplifies its own promoter, so past a threshold the programme completes whether or not RANKL is still present. That is why anti-resorptive treatment prevents new osteoclasts rather than switching off existing ones, and why the clinical effect lags the pharmacology by weeks. OSCAR supplies the ITAM-dependent calcium flux NFATc1 requires \u2014 co-stimulation, on a cell with no antigen receptor, borrowed wholesale from immune signalling. Below that the machinery is mechanical: \u03b1v\u03b23 forms the sealing zone, carbonic anhydrase II dissolves the mineral, and only then does cathepsin K reach the collagen. Acid first, protease second \u2014 which is why carbonic anhydrase II deficiency causes osteopetrosis just as cathepsin K deficiency does.

The In Vivo tie-in, and where it sits. 11 of the 35 nodes carry a functional-grade antibody, and they are concentrated at the decision points rather than scattered. RANKL is blockable in both species \u2014 a functional-grade anti-mouse RANKL antibody for models and the VivoGenie anti-human RANKL, the denosumab sequence, for human systems \u2014 which makes this one of the few maps in the library where the intervention and the mechanism are the same molecule. Around it: CD115 and CD11b on the precursor, TNF ultra-low endotoxin (necessary here, because LPS drives osteoclastogenesis through TLR4 on its own and would be scored as the cytokine's effect), IL-1\u03b2 and IL-1R1 as a ligand-versus-receptor pair, CD4, IFN-\u03b3, CTLA-4 \u2014 which acts on the precursor directly and not only through T cells \u2014 and pan-TGF-\u03b2, the coupling factor released from the matrix as it is resorbed. Stated plainly, what is not blockable here: IL-6, IL-17A, IL-23, OPG, M-CSF, RANK itself, sclerostin and DKK1. What compensates is that the measurement layer is unusually complete \u2014 cathepsin K, TRAP, MMP-9, CAII, osteopontin, CTX-I, sclerostin, DKK1, RUNX2, bone ALP and osteocalcin. The design this range supports is therefore to intervene above the membrane and read out below it. One assay caution worth stating: CTX-I is strongly diurnal and suppressed by food, so an unfasted afternoon sample and a fasted morning one are not comparable. For research use only; not for use in diagnostic or therapeutic procedures.